US Bancorp DE raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,118,454 shares of the biopharmaceutical company’s stock after purchasing an additional 33,981 shares during the period. US Bancorp DE’s holdings in Gilead Sciences were worth $80,126,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in GILD. Welch Investments LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $108,000. Wealthcare Advisory Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $133,000. Horan Capital Advisors LLC. bought a new position in shares of Gilead Sciences in the 3rd quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences in the 2nd quarter worth about $147,000. Finally, Hanson & Doremus Investment Management raised its position in shares of Gilead Sciences by 806.5% in the 3rd quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares in the last quarter. 77.96% of the stock is owned by institutional investors and hedge funds.
In other Gilead Sciences news, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $78.69, for a total transaction of $1,967,250.00. Following the completion of the transaction, the executive vice president now owns 69,426 shares in the company, valued at approximately $5,463,131.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $80.93, for a total value of $472,064.69. The disclosure for this sale can be found here. Insiders have sold a total of 430,268 shares of company stock valued at $34,074,395 in the last quarter. Company insiders own 1.30% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.11. The business had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.70 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 6.21 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 29th. Shareholders of record on Friday, March 16th will be paid a dividend of $0.57 per share. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 dividend on an annualized basis and a yield of 2.79%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. Gilead Sciences’s payout ratio is 59.77%.
Several research analysts have recently weighed in on the company. Barclays reissued an “overweight” rating and issued a $95.00 price objective (up from $90.00) on shares of Gilead Sciences in a research report on Tuesday, March 6th. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Royal Bank of Canada reissued a “buy” rating and issued a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann reissued a “market perform” rating and issued a $80.00 price objective (down from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, ten have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $88.61.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.